This page has beta status

TD COST Action TD1402
Multifunctional Nanoparticles for Magnetic Hyperthermia and Indirect Radiation Therapy (RADIOMAG)

The Action aims to bring together and to organise the research outcomes from the different participating network members in a practical way to provide clinicians with the necessary input to trial a novel anti-cancer treatment combining magnetic hyperthermia and radiotherapy, also identifying future research objectives upon appraisal of the obtained results. Feedback between the different working groups here is essential, and is expected that the lifetime of this Action proposal will eventually result in a compendium of best practices for magnetic hyperthermia.

RADIOMAG will generate new and strengthen the existing synergies between technical advances (thermal imaging / MH), new treatment concepts (combined targeting radiosensitisation and magnetic thermotherapy) and biocompatible coating in order to achieve a breakthrough in the clinical application of magnetic hyperthermia. Due to the complexity of this aim, synergies can only be achieved on a longer time frame, by means of workshops, STSMs, joint publications, common Horizon 2020 research proposals and exchange with other COST Actions (e.g. TD1004, TD1205).

(Descriptions are provided by the Actions directly via e-COST.)


General Information*

Chair of the Action:

Dr Simo SPASSOV (BE)

Vice Chair of the Action:

Dr Daniel ORTEGA (ES)

Science officer of the Action:

Dr Mónica PÉREZ-CABERO

Administrative officer of the Action:

Ms Carmencita MALIMBAN

Downloads*

Action Fact Sheet

Download AFS as .RTF

Memorandum of Understanding

Download MoU as PDF

Websites*

* content provided by e-COST.
Data is synchronised once per night.

Tools

Last updated: 17 May 2014 top of page